Sponsor: Bristol Myers Squibb
Sponsor Study ID: CA224-098
Study Title: A Phase 3, Randomized, Double blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III IV Melanoma (RELATIVITY 098)
CTO #: 103487
NCT Number: NCT05002569
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Melanoma, Skin
Study Objectives: The purpose of this study is to assess relatlimab and nivolumab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma.